|
|
|
2008 Small Cap Equity Conference
Presenter |
|
We would like to thank this company for
presenting at our 5th Annual Small Cap Equity Conference
held May 6th, 2008 at the Le
Parker Meridien New York City. If you missed the event, you can still
hear the presentations via our streaming audio archive.
Click
here Listen! |
|
Taglich's Company Profile
for: |
www.dermasciences.com
|
Derma Sciences, Inc. |
Symbol:
DSCI
Analyst:
Juan Noble
Taglich Rating:
Speculative Buy
Price Target:
$1.40
Time Horizon:
12 Months
Rating Established:
July 10, 2006
Price When Established:
$0.82
Most Recent Report:
April 16, 2008
Price When Issued:
$0.99
|
|
|
Most Recent Update |
|
Updated Earnings
Note (Dated April 16, 2008) |
|
What's New |
|
On May 7, 2008, the company announced a
three-year supply agreement for its MediHoney line with St
Louis, MO-based Amerinet Inc., a national healthcare group
purchasing organization (GPO) that serves more than 26,000 acute
and non-acute health care providers nationwide.
The Amerinet
agreement is the second such deal announced by the company. A
three-year agreement with agreement with GPO MedAssets Supply
Chain Systems, a MedAssets company (Nasdaq: MDAS), starts June
1, 2008.
On April 23, 2008, the company announced
that it signed a multi-year supply agreement with group
purchasing organization MedAssets Supply Chain Systems, a
MedAssets company (Nasdaq: MDAS). The 3-year agreement, which
starts June 1, 2008, will help to introduce MediHoney to
MedAssets’ customer base of more than 125 health systems, 2,500
hospitals and 30,000 non-acute care healthcare providers. |
|
Company Description |
Derma Sciences, Inc. (OTC BB: DSCI), was established in 1984 to manufacture and market wound care products used to treat pressure ulcers, diabetic and venous ulcers, surgical incisions and serious burns. Since 1996, Derma Sciences has expanded its product line and manufacturing base through some acquisitions. The company’s production facilities are in Canada and China. Contractors in China are being used increasingly to perform the more costly sterilization procedures.
The company’s product line is sold mainly through distributors in the US and Canada to end users such as nursing homes and acute care hospitals, with some sales made to clinics and physicians’ offices. |
|
Taglich Research Reports |
Updated Earnings
Note (Dated April 2, 2008)
Updated Research
Report (Dated December 14, 2007)
Updated Earnings
Note (Dated November 14, 2007)
Updated Research Report (Dated
September 24, 2007)
Updated Research Report (Dated
June 13, 2007)
Updated Research Report (Dated
April 13, 2007)
Updated Research Report (Dated
December 26, 2006)
Updated Research Report (Dated
September 12, 2006)
Initial Research Report (Dated
July 10, 2006)
All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click
here)
*The information and statistical data
contained herein have been obtained from sources, which we believe to be
reliable but in no way are warranted by us as to accuracy or
completeness. We do not undertake to advise you as to changes in figures
or our views. This is not a solicitation of any order to buy or sell.
Taglich Brothers, Inc. is fully disclosed with its clearing firm,
Pershing, LLC, is not a market maker and does not sell to or buy from
customers on a principal basis. The above statements are the opinion of
Taglich Brothers, Inc. and are not a guarantee that the target price for
the stock will be met or that predicted business results for the company
will occur. There may be instances when fundamental, technical and
quantitative opinions contained in the reports are not in concert. We,
our affiliates, any officer, director or stockholder or any member of
their families may from time to time purchase or sell any of the
above-mentioned or related securities. Analysts and members of the
Research Department are prohibited from buying or selling securities
issued by the companies that Taglich Brothers, Inc. has a research
relationship with, except if ownership of such securities was prior to
the start of such relationship, then an Analyst or member of the
Research Department may sell such securities after obtaining expressed
written permission from the Director of Research. All research issued by
Taglich Brothers, Inc. is based on public information. In April 2006,
Taglich Brothers underwrote an offering of 7,548,064 Derma Sciences’
common shares at $0.60 per share and 1,887,016 warrants exercisable at
$1.00 per share. In March, 2006, the company paid a monetary engagement fee of $21,000 (USD)
for the first year of creation and dissemination of research reports and
since July, 2007, has paid a monthly monetary fee of $1,750 (USD) to Taglich Brothers,
Inc. for these services after the first year. For further information
and Taglich Brothers, Inc. ownership data please refer to each
individual report. |
|
Send this Page to a friend |
|
To send this page to a friend, just fill out the form below and press
the "send it" button!
|
|
|
Taglich Covered Companies |
AeroCentury Corp.
Anglo Swiss Resources, Inc.
Avensys Corporation
BioForce Nanosci. Holdings, Inc.
Caneum Inc.
Cardium Therapeutics, Inc.
China 3C Group
Command Security Corp.
CTI Industries Corp
Derma Sciences, Inc.
DRI Corporation
EnerLume Energy Mgt. Corp.
EP MedSystems, Inc.
Exeter Resource Corp.
GammaCan International, Inc.
Hartmarx Corporation
Helios & Matheson North America
INX, Inc.
Leading Brands, Inc.
Life Partners Holdings, Inc.
Lifeway Foods, Inc.
Littlefield Corporation
Manchester, Inc.
MFIC Corporation
Orchids Paper Products
Park City Group, Inc.
Pressure BioSciences, Inc.
QPC Lasers, Inc.
Radiant Logistics, Inc.
Reed's Inc.
Salon Media Group, Inc.
Simulations Plus, Inc.
TranSwitch Corporation
Triton Dist. Sys., Inc.
UFP Technologies, Inc.
US 1 Industries, Inc.
Wave Systems Corp.
Williams Controls, Inc.
|
|
